Plain-English translation of NCT05674994 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether methylprednisolone (a steroid medication) can help treat acute exacerbations—sudden, serious flare-ups—in people with idiopathic pulmonary fibrosis (a chronic lung disease causing scarring). Half of participants will receive the medication and half will receive a placebo (an inactive treatment) to see if the medication actually helps improve outcomes.
Right now, doctors often use steroids to treat these dangerous lung flare-ups, but there's no solid proof that the medication actually works. Some recent studies have even questioned whether it helps at all. This trial is needed to find out for certain whether this treatment is truly beneficial.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will be randomly assigned to receive either the steroid medication or a placebo. You will receive intravenous (IV) infusions on the first three days, then take oral pills for the remaining 27 days while the dose is gradually reduced. During this time, you'll have medical visits and monitoring to track how you respond and whether your breathing improves.
AI-generated summary from trial data · Jun 17, 2026 · Not medical advice
France